Back to Search Start Over

Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer:The potential value of prognostic molecular markers

Authors :
Geraldine R. Vink
Miriam Koopman
Marjolein J.E. Greuter
Cornelis J A Punt
Jan Paul Medema
Gabrielle Jongeneel
Louis Vermeulen
Veerle M.H. Coupé
Jan N. M. IJzermans
Felice N. van Erning
Natalia Kunst
Center of Experimental and Molecular Medicine
Radiotherapy
Oncology
Amsterdam Gastroenterology Endocrinology Metabolism
CCA - Cancer Treatment and Quality of Life
Epidemiology and Data Science
Orthopedic Surgery and Sports Medicine
APH - Methodology
CCA - Imaging and biomarkers
CCA - Cancer Treatment and quality of life
Surgery
Source :
Jongeneel, G, Greuter, M J E, Kunst, N, Van Erning, F N, Koopman, M, Medema, J P, Vermeulen, L, Ijzermans, J N M, Vink, G R, Punt, C J A & Coupé, V M H 2021, ' Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer : The potential value of prognostic molecular markers ', Cancer Epidemiology Biomarkers and Prevention, vol. 30, no. 9, pp. 1726-1734 . https://doi.org/10.1158/1055-9965.EPI-21-0078, Cancer Epidemiology Biomarkers and Prevention, 30(9), 1726-1734. American Association for Cancer Research Inc., Cancer Epidemiol Biomarkers Prev, Cancer Epidemiology Biomarkers and Prevention, 30(9), 1726-1734
Publication Year :
2021

Abstract

Background: To explore the potential value of consensus molecular subtypes (CMS) in stage II colon cancer treatment selection, we carried out an early cost-effectiveness assessment of a CMS-based strategy for adjuvant chemotherapy. Methods: We used a Markov cohort model to evaluate three selection strategies: (i) the Dutch guideline strategy (MSS+pT4), (ii) the mutation-based strategy (MSS plus a BRAF and/or KRAS mutation or MSS plus pT4), and (iii) the CMS-based strategy (CMS4 or pT4). Outcomes were number of colon cancer deaths per 1,000 patients, total discounted costs per patient (pp), and quality-adjusted life-years (QALY) pp. The analyses were conducted from a Dutch societal perspective. The robustness of model predictions was assessed in sensitivity analyses. To evaluate the value of future research, we performed a value of information (VOI) analysis. Results: The Dutch guideline strategy resulted in 8.10 QALYs pp and total costs of €23,660 pp. The CMS-based and mutation-based strategies were more effective and more costly, with 8.12 and 8.13 QALYs pp and €24,643 and €24,542 pp, respectively. Assuming a threshold of €50,000/QALY, the mutation-based strategy was considered as the optimal strategy in an incremental analysis. However, the VOI analysis showed substantial decision uncertainty driven by the molecular markers (expected value of partial perfect information: €18M). Conclusions: On the basis of current evidence, our analyses suggest that the mutation-based selection strategy would be the best use of resources. However, the extensive decision uncertainty for the molecular markers does not allow selection of an optimal strategy at present. Impact: Future research is needed to eliminate decision uncertainty driven by molecular markers.

Details

Language :
English
ISSN :
10559965
Database :
OpenAIRE
Journal :
Jongeneel, G, Greuter, M J E, Kunst, N, Van Erning, F N, Koopman, M, Medema, J P, Vermeulen, L, Ijzermans, J N M, Vink, G R, Punt, C J A & Coupé, V M H 2021, ' Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer : The potential value of prognostic molecular markers ', Cancer Epidemiology Biomarkers and Prevention, vol. 30, no. 9, pp. 1726-1734 . https://doi.org/10.1158/1055-9965.EPI-21-0078, Cancer Epidemiology Biomarkers and Prevention, 30(9), 1726-1734. American Association for Cancer Research Inc., Cancer Epidemiol Biomarkers Prev, Cancer Epidemiology Biomarkers and Prevention, 30(9), 1726-1734
Accession number :
edsair.doi.dedup.....291430f09591738742cfd1e86e2bf290
Full Text :
https://doi.org/10.1158/1055-9965.EPI-21-0078